Nxera Pharma CoSOLTF 85 Gross Margin % is 75.69% as of Mar. 2026, which is 17% below its 10-year median of 91.32. GuruFocus rates SOLTF with a GF Score™ of 85/100 and a GF Value™ of $7.79 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 737 Biotechnology companies, Nxera Pharma Co ranks better than 62.42% on this metric.
Nxera Pharma Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -5.9%.
The historical rank and industry rank for Nxera Pharma Co's Gross Margin % or its related term are showing as below:
SOLTF'
s Gross Margin % Range Over the Past 10 Years
Min: 72.32 Med: 91.32 Max: 99.95
Current: 72.32
During the past 13 years, the highestGross Margin % of Nxera Pharma Co was 99.95%. The lowest was 72.32%. And the median was 91.32%.
SOLTF's Gross Margin % is ranked better than 62.42% of 737
companies
in the Biotechnology industry
Industry Median: 60.92
vs SOLTF: 72.32
Nxera Pharma Co had a gross margin of 75.69% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Nxera Pharma Co was -5.90% per year.
Nxera Pharma Co (OTCPK:SOLTF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nxera Pharma Co had a gross margin of 75.69% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Nxera Pharma Co Gross Margin % Related Terms
Nxera Pharma Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Nxera Pharma Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOLTF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Nxera Pharma Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nxera Pharma Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Nxera Pharma Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nxera Pharma Co (SOLTF) has a Gross Margin % of 75.69% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Nxera Pharma Co and its competitors. This is 17% below median its historical median of 91.32. Over the past decade, Nxera Pharma Co's Gross Margin % has ranged from 72.32 to 99.95. According to the industry distribution chart, Nxera Pharma Co ranks #277 out of 737 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Nxera Pharma Co's Gross Margin % too high?
Nxera Pharma Co's current Gross Margin % of 75.69% is 17% below median its 10-year median of 91.32. Over the past 10 years, this metric has ranged from a low of 72.32 to a high of 99.95. The Biotechnology industry median Gross Margin % is 60.92. Nxera Pharma Co's value of 75.69% is 24.2% above this industry median. Based on the distribution chart, Nxera Pharma Co ranks #277 out of 737 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nxera Pharma Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nxera Pharma Co ranks #277 out of 737 companies for Gross Margin %. This puts Nxera Pharma Co in the upper half of its industry. The industry median Gross Margin % is 60.92. Nxera Pharma Co's value of 75.69% is 24.2% above this benchmark. Historically, Nxera Pharma Co's own Gross Margin % has ranged from 72.32 to 99.95 over the past decade. While the company's 10-year median is 91.32 vs. the industry median of 60.92, Nxera Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nxera Pharma Co's current Gross Margin % of 75.69% is 24.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Nxera Pharma Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nxera Pharma Co's current Gross Margin % is 75.69%, which is 17% below median its own 10-year median of 91.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Nxera Pharma Co (SOLTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.79, compared to a current price of $6.37 — trading 18.2% below its estimated fair value. The current Gross Margin % is 75.69%, which is 17% below median its 10-year median of 91.32 and 24.2% above the Biotechnology industry median of 60.92. Nxera Pharma Co's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Nxera Pharma Co (SOLTF), the current Gross Margin % is 75.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nxera Pharma Co (SOLTF) Overvalued in 2026?
Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued.
The current stock price of $6.37 is trading 18.2% below its estimated GF Value™ of $7.79.
GuruFocus considers Nxera Pharma Co to be Modestly Undervalued.
Key valuation signals for SOLTF:
Gross Margin %: 75.69% (17% below median its 10-year median of 91.32)
GF Value™: $7.79 vs. price of $6.37 (18.2% below fair value)
Industry Position: 24.2% above the Biotechnology median (#277 of 737)
No single metric tells the full story. See the SOLTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
85GF Score
Get the complete analysis for SOLTF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOLTF has been successfully added to your 
